Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 13/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | CCR2 | P41597 | 1/20 | 0.56 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17929342 | 0.86 | CXCR4 (0.61) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL20806665 | 0.81 | CXCR4 (0.51) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL25978396 | 0.80 | CXCR4 (0.48) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL28129042 | 0.80 | HCRTR1 (0.56) | CHRM2CHRM3 | |
| SCHEMBL3036998 | 0.79 | CHKA (0.62) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Hydrochloric Acid SCHEMBL20305004 | 0.78 | CXCR4 (0.62) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL28129028 | 0.78 | CHRM3 (0.43) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL23696156 | 0.77 | CHRM3 (0.49) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL25145993 | 0.76 | LMNA (0.54) | MEN1CHRM2KMT2ACHRM3KDM4E | |
| SCHEMBL6708106 | 0.76 | MCHR1 (0.49) | KDM4EALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717540-B2 | Modified immune cells and uses thereof | ISI LIFE SCIENCES, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717540-B2 | Modified immune cells and uses thereof | ISI LIFE SCIENCES, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20200297765-A1 | MODIFIED IMMUNE CELLS AND USES THEREOF | ISI LIFE SCIENCES, INC. | 2020-09-24 | — | — | US | disclosed |
| US-20160206592-A1 | METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS BY INHIBITION OF CXCR4/CXCL12 SIGNALING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-07-21 | — | — | US | disclosed |
| US-20160206592-A1 | METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS BY INHIBITION OF CXCR4/CXCL12 SIGNALING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297765-A1 | MODIFIED IMMUNE CELLS AND USES THEREOF | CD47, CD4, CD74 | CXCR4 1049/4885MEN1 1791/4885CHRM2 2673/4885 |
| US-20160206592-A1 | METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS BY INHIBITION OF CXCR4/CXCL12 SIGNALING | CXCL12, GRM2, GRM1 | CXCR4 5/4885MEN1 4840/4885CHRM2 1329/4885 |
| US-11717540-B2 | Modified immune cells and uses thereof | CD47, CD4, CD74 | CXCR4 1049/4885MEN1 1791/4885CHRM2 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.